title: A Patient With Parenteral Nutrition-Dependent Short Bowel Syndrome and Cardiovascular Disease With 4-Year Exposure to Teduglutide.
abstract: Clinical trials of the glucagon-like peptide 2 analogue teduglutide resulted in approval of the drug by the Food and Drug Administration in 2012 as a treatment for parenteral nutrition-dependent short bowel syndrome in adults. This report presents the case study of a man with short bowel syndrome caused by portal vein thrombosis who had 4 years exposure to the drug at the time of his death due to cardiovascular disease.
authors.affiliation: University of Pennsylvania, School of Nursing, Philadelphia, Pennsylvania University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania Hospital of the University of Pennsylvania, Clinical Nutrition Support Service, Philadelphia, Pennsylvania compherc@nursing.upenn.edu.
authors.forename: Charlene
authors.initials: C
authors.lastname: Compher
authors.affiliation: University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania Hospital of the University of Pennsylvania, Department of Pathology and Laboratory Medicine, Philadelphia, Pennsylvania.
authors.forename: Katherine Boothe
authors.initials: KB
authors.lastname: Levinson
authors.affiliation: University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania Hospital of the University of Pennsylvania, Department of Pathology and Laboratory Medicine, Philadelphia, Pennsylvania.
authors.forename: Carolyn L
authors.initials: CL
authors.lastname: Cambor
authors.affiliation: Hospital of the University of Pennsylvania, Clinical Nutrition Support Service, Philadelphia, Pennsylvania.
authors.forename: Nancy
authors.initials: N
authors.lastname: Stoner
authors.affiliation: University of Pennsylvania, School of Nursing, Philadelphia, Pennsylvania Hospital of the University of Pennsylvania, Clinical Nutrition Support Service, Philadelphia, Pennsylvania.
authors.forename: Joseph I
authors.initials: JI
authors.lastname: Boullata
authors.affiliation: University of Pennsylvania, School of Nursing, Philadelphia, Pennsylvania.
authors.forename: Amanda
authors.initials: A
authors.lastname: Piarulli
authors.affiliation: University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania Hospital of the University of Pennsylvania, Clinical Nutrition Support Service, Philadelphia, Pennsylvania Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
authors.forename: Bruce
authors.initials: B
authors.lastname: Kinosian
mesh_terms: D002318:Cardiovascular Diseases / Q000150:complications*; D017809:Fatal Outcome; D005765:Gastrointestinal Agents; D006333:Heart Failure; D006801:Humans; D008297:Male; D008875:Middle Aged; D010288:Parenteral Nutrition; D010455:Peptides / Q000009:adverse effects / Q000627:therapeutic use*; D011169:Portal Vein; D016032:Randomized Controlled Trials as Topic; D012778:Short Bowel Syndrome / Q000209:etiology / Q000628:therapy*; D013927:Thrombosis / Q000150:complications
chemical_list: D005765:Gastrointestinal Agents; D010455:Peptides; C494910:teduglutide
keywords: cardiovascular; glucagon-like peptide 2; growth factors; malabsorption; short bowel syndrome; teduglutide